feedback

Course Director

Ruben A. Mesa, MD, FACP
Ruben A. Mesa, MD, FACP

Mays Cancer Center at UT Health San Antonio MD Anderson
San Antonio, Texas

Faculty

Prithviraj Bose
Prithviraj Bose, MD

The University of Texas MD Anderson Cancer Center
Houston, Texas

Aaron T. Gerds
Aaron T. Gerds, MD, MS

Cleveland Clinic Taussig Cancer Institute
Case Comprehensive Cancer Center
Cleveland, Ohio

Accredited by

Medical Learning Institute, Inc.

View Activity Materials

Activity Description

The recent approval of newer JAK inhibitors and new evidence on emerging JAK-targeting strategies have raised additional questions over optimized treatment selection in myelofibrosis (MF) and awareness of clinical factors that can influence therapeutic selection. Additionally, newer dynamic risk-assessment models have allowed for more precise characterization of this disease at diagnosis and during the treatment course. In the wake of these advances, understanding how to effectively personalize therapeutic management based on the modern diagnostic and risk-assessment tools while ensuring safe usage of JAK inhibitors is crucial to maximizing beneficial patient outcomes in MF.

In a recent live webcast, our panel of experts used the latest real-world evidence to confirm the core therapeutic role for JAK inhibitor–based strategies in MF, highlighting modern diagnostic and risk-assessment strategies that have informed an individualized treatment approach. During a unique practicum session, the panel offered practice strategies using real-world case scenarios, walking through selection of JAK inhibitor–based options across the MF disease continuum to improve patient outcomes.

Target Audience

This activity has been designed to meet the educational needs of hematologist-oncologists and other clinicians involved in the management of myelofibrosis.

Educational Objectives

Upon completion of this activity, participants should be better able to:
  • Recognize clinical and molecular/mutational features that can be used for diagnosis and risk stratification in myelofibrosis
  • Review the latest efficacy and safety evidence about approved and emerging JAK inhibitors as well as other targeted therapies in the management of myelofibrosis
  • Design safe, risk-adapted treatment regimens for patients with symptomatic and asymptomatic myelofibrosis, including those refractory to front-line JAK inhibitor therapy

Providership, Credit, and Support


This CME/MOC activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.

This activity is supported through an educational grant from Bristol Myers Squibb.

Physician Continuing Medical Education

ACCMEThis activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOCSuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC Credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared with ABIM through the ACCME’s Program and Activity Reporting System (PARS). Blinded individual or aggregated participant data may be shared with the funder of the activity.

Faculty Disclosures

Chair
Ruben A. Mesa, MD, FACP
Director
Mays Cancer Center at UT Health San Antonio MD Anderson
Mays Family Foundation Distinguished University Presidential Chair
Professor of Medicine
San Antonio, Texas

Ruben A. Mesa, MD, FACP, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Blueprint Medicines Corporation; Genentech, Inc.; Novartis Pharmaceuticals Corporation; and Sierra Oncology, Inc.
Grant/Research Support from AbbVie Inc.; Celgene Corporation; CTI BioPharma Corp.; Incyte Corporation; and Promedior, Inc.

Faculty
Prithviraj Bose, MD
Associate Professor, Department of Leukemia, Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas

Prithviraj Bose, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Celgene Corporation (now Bristol Myers Squibb); CTI BioPharma Corp.; Incyte Corporation; and Kartos Therapeutics.
Grant/Research Support from Astellas Pharmaceuticals; Blueprint Medicines Corporation; Celgene Corporation (now Bristol Myers Squibb); Constellation Pharmaceuticals; CTI BioPharma Corp.; Incyte Corporation; Kartos Therapeutics; NS Pharma; Pfizer, Inc.; and Promedior, Inc.

Aaron T. Gerds, MD, MS
Assistant Professor, Department of Medicine
Cleveland Clinic Taussig Cancer Institute
Medical Director, Clinical Research Office, Case Comprehensive Cancer Center
Cleveland, Ohio

Aaron T. Gerds, MD, MS, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Celgene Corporation; CTI BioPharma Corp.; Kartos Therapeutics; PharmaEssentia; and Promedior, Inc.
Grant/Research Support from Celgene Corporation; CTI BioPharma Corp.; Incyte Corporation and Sierra Oncology, Inc.

Planning Committee Disclosures

The planners from Medical Learning Institute, Inc., the accredited provider, and PeerView Institute for Medical Education, the joint provider, do not have any financial relationships with an ACCME-defined commercial interest related to the content of this accredited activity during the past 12 months unless listed below.

Content/Peer Reviewer Disclosures

The following Content/Peer Reviewers have nothing to disclose:

Natalie I. Vokes, MD
Stacy L. Sims, MSN, RN, CMCN

Disclosure of Unlabeled Use

This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Method of Participation

There are no fees for participating in or receiving credit for this accredited activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. A score of 70% or higher is needed to obtain MOC credit. There are no prerequisites and there is no fee to participate in this activity or to receive MOC credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

About This CME/MOC Activity

PVI, PeerView Institute for Medical Education, and Medical Learning Institute, Inc. are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Medical Learning Institute, Inc.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2020, PeerView

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.